Do analysts rate APTA or HVO?

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 153.81%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Aptamer Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptamer Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation & earnings, APTA or HVO?

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptamer Group £1.38M 8.48 -£14.17M -£0.11 N/A hVIVO £38.85M 1.05 £17.84M -£0.87 N/A

Is APTA or HVO more profitable?

hVIVO has a net margin of -31.76% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -35.13% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets Aptamer Group -178.52% -135.35% -44.96% hVIVO -31.76% -35.13% 11.97%

Does the media favor APTA or HVO?

In the previous week, Aptamer Group and Aptamer Group both had 1 articles in the media. hVIVO's average media sentiment score of 0.00 beat Aptamer Group's score of -0.63 indicating that hVIVO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptamer Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative hVIVO 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer APTA or COIL?

In the previous week, Roquefort Therapeutics had 4 more articles in the media than Aptamer Group. MarketBeat recorded 5 mentions for Roquefort Therapeutics and 1 mentions for Aptamer Group. Roquefort Therapeutics' average media sentiment score of 0.61 beat Aptamer Group's score of -0.63 indicating that Roquefort Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptamer Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Roquefort Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer APTA or HEMO?

In the previous week, Hemogenyx Pharmaceuticals had 5 more articles in the media than Aptamer Group. MarketBeat recorded 6 mentions for Hemogenyx Pharmaceuticals and 1 mentions for Aptamer Group. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Aptamer Group's score of -0.63 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptamer Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Hemogenyx Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, APTA or DDDD?

Aptamer Group has higher revenue and earnings than 4D pharma. Aptamer Group is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptamer Group £1.38M 8.48 -£14.17M -£0.11 N/A 4D pharma £718K 0.00 -£31.94M -£15.40 N/A

Is APTA or DDDD more profitable?

4D pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. 4D pharma's return on equity of -89.48% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets Aptamer Group -178.52% -135.35% -44.96% 4D pharma N/A -89.48% -42.64%

Does the media prefer APTA or DDDD?

In the previous week, Aptamer Group and Aptamer Group both had 1 articles in the media. 4D pharma's average media sentiment score of 0.00 beat Aptamer Group's score of -0.63 indicating that 4D pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aptamer Group 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative 4D pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aptamer Group (APTA) Competitors

GBX 0.34 +0.03 (+8.71%)

As of 12:31 PM Eastern

Compare

APTA vs. HVO, COIL, HEMO, C4XD, and DDDD

Should you buy Aptamer Group stock or one of its competitors? Aptamer Group's main competitors and comparable companies include hVIVO (HVO), Roquefort Therapeutics (COIL), Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to hVIVO?

Aptamer Group (LON:APTA) and hVIVO (LON:HVO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

hVIVO has a consensus price target of GBX 15, suggesting a potential upside of 153.81%. Given hVIVO's stronger consensus rating and higher probable upside, analysts plainly believe hVIVO is more favorable than Aptamer Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptamer Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

3.4% of Aptamer Group shares are held by institutional investors. Comparatively, 12.7% of hVIVO shares are held by institutional investors. 7.6% of Aptamer Group shares are held by company insiders. Comparatively, 4.9% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

hVIVO has a net margin of -31.76% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -35.13% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
hVIVO	-31.76%	-35.13%	11.97%

In the previous week, Aptamer Group and Aptamer Group both had 1 articles in the media. hVIVO's average media sentiment score of 0.00 beat Aptamer Group's score of -0.63 indicating that hVIVO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptamer Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
hVIVO	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	8.48	-£14.17M	-£0.11	N/A
hVIVO	£38.85M	1.05	£17.84M	-£0.87	N/A

Aptamer Group has a beta of 0.871, suggesting that its share price is 13% less volatile than the broader market. Comparatively, hVIVO has a beta of 1.694, suggesting that its share price is 69% more volatile than the broader market.

Summary

hVIVO beats Aptamer Group on 11 of the 15 factors compared between the two stocks.

How does Aptamer Group compare to Roquefort Therapeutics?

Aptamer Group (LON:APTA) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Aptamer Group has a net margin of -178.52% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

Roquefort Therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	8.48	-£14.17M	-£0.11	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

3.4% of Aptamer Group shares are held by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are held by institutional investors. 7.6% of Aptamer Group shares are held by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Roquefort Therapeutics had 4 more articles in the media than Aptamer Group. MarketBeat recorded 5 mentions for Roquefort Therapeutics and 1 mentions for Aptamer Group. Roquefort Therapeutics' average media sentiment score of 0.61 beat Aptamer Group's score of -0.63 indicating that Roquefort Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptamer Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Roquefort Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aptamer Group has a beta of 0.871, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market.

Summary

Roquefort Therapeutics beats Aptamer Group on 7 of the 12 factors compared between the two stocks.

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Aptamer Group (LON:APTA) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Aptamer Group has a beta of 0.871, meaning that its share price is 13% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, meaning that its share price is 49% more volatile than the broader market.

In the previous week, Hemogenyx Pharmaceuticals had 5 more articles in the media than Aptamer Group. MarketBeat recorded 6 mentions for Hemogenyx Pharmaceuticals and 1 mentions for Aptamer Group. Hemogenyx Pharmaceuticals' average media sentiment score of 0.37 beat Aptamer Group's score of -0.63 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptamer Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Hemogenyx Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Aptamer Group. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	8.48	-£14.17M	-£0.11	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

3.4% of Aptamer Group shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 7.6% of Aptamer Group shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Hemogenyx Pharmaceuticals beats Aptamer Group on 7 of the 12 factors compared between the two stocks.

How does Aptamer Group compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Aptamer Group had 1 more articles in the media than C4X Discovery. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for C4X Discovery. C4X Discovery's average media sentiment score of 0.00 beat Aptamer Group's score of -0.63 indicating that C4X Discovery is being referred to more favorably in the media.

Company	Overall Sentiment
C4X Discovery	Neutral
Aptamer Group	Negative

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 3.4% of Aptamer Group shares are held by institutional investors. 27.1% of C4X Discovery shares are held by insiders. Comparatively, 7.6% of Aptamer Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.871, indicating that its stock price is 13% less volatile than the broader market.

C4X Discovery has a net margin of 42.81% compared to Aptamer Group's net margin of -178.52%. C4X Discovery's return on equity of 55.38% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4X Discovery	42.81%	55.38%	28.04%
Aptamer Group	-178.52%	-135.35%	-44.96%

C4X Discovery has higher revenue and earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4X Discovery	£24.68M	0.00	£10.57M	£0.04	N/A
Aptamer Group	£1.38M	8.48	-£14.17M	-£0.11	N/A

Summary

C4X Discovery beats Aptamer Group on 10 of the 12 factors compared between the two stocks.

How does Aptamer Group compare to 4D pharma?

Aptamer Group (LON:APTA) and 4D pharma (LON:DDDD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Aptamer Group has higher revenue and earnings than 4D pharma. Aptamer Group is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	8.48	-£14.17M	-£0.11	N/A
4D pharma	£718K	0.00	-£31.94M	-£15.40	N/A

3.4% of Aptamer Group shares are owned by institutional investors. Comparatively, 26.8% of 4D pharma shares are owned by institutional investors. 7.6% of Aptamer Group shares are owned by insiders. Comparatively, 12.2% of 4D pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

4D pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. 4D pharma's return on equity of -89.48% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
4D pharma	N/A	-89.48%	-42.64%

Aptamer Group has a beta of 0.871, meaning that its stock price is 13% less volatile than the broader market. Comparatively, 4D pharma has a beta of 2.63, meaning that its stock price is 163% more volatile than the broader market.

In the previous week, Aptamer Group and Aptamer Group both had 1 articles in the media. 4D pharma's average media sentiment score of 0.00 beat Aptamer Group's score of -0.63 indicating that 4D pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aptamer Group	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
4D pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

4D pharma beats Aptamer Group on 8 of the 11 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APTA vs. The Competition

Export

Metric	Aptamer Group	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£11.69M	£3.83B	£7.11B	£2.80B
Dividend Yield	N/A	3.64%	2.53%	6.18%
P/E Ratio	-3.06	13.27	274.41	366.17
Price / Sales	8.48	1,290.28	608.04	89,425.29
Price / Cash	N/A	121.76	77.38	27.89
Price / Book	1.58	16.63	10.90	6.83
Net Income	-£14.17M	-£22.67M	£3.50B	£5.89B
7 Day Performance	1.81%	-3.00%	-2.15%	-0.75%
1 Month Performance	-10.85%	-10.71%	-6.41%	16.85%
1 Year Performance	-51.51%	21.33%	8.88%	16.40%

Aptamer Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APTA Aptamer Group	N/A	GBX 0.34 +8.7%	N/A	-56.5%	£11.69M	£1.38M	N/A	30
HVO hVIVO	1.2437 of 5 stars	GBX 6 -0.8%	GBX 15 +150.0%	-21.3%	£41.30M	£38.85M	N/A	N/A	Gap Up
COIL Roquefort Therapeutics	N/A	GBX 7.60 -5.0%	N/A	-60.1%	£32.44M	N/A	N/A	9	Earnings Report
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 470 +2.2%	N/A	-53.4%	£31.96M	N/A	N/A	14	Earnings Report Gap Down
C4XD C4X Discovery	N/A	N/A	N/A	N/A	£30.27M	£24.68M	300.00	49	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:APTA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptamer Group (APTA) Competitors

APTA vs. HVO, COIL, HEMO, C4XD, and DDDD

How does Aptamer Group compare to hVIVO?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Summary

How does Aptamer Group compare to C4X Discovery?

Summary

How does Aptamer Group compare to 4D pharma?

Summary

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptamer Group (APTA) Competitors

APTA vs. HVO, COIL, HEMO, C4XD, and DDDD

How does Aptamer Group compare to hVIVO?

Do analysts rate APTA or HVO?

Do insiders and institutionals have more ownership in APTA or HVO?

Is APTA or HVO more profitable?

Does the media favor APTA or HVO?

Which has preferable valuation & earnings, APTA or HVO?

Which has more risk & volatility, APTA or HVO?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Is APTA or COIL more profitable?

Which has higher valuation and earnings, APTA or COIL?

Do institutionals and insiders hold more shares of APTA or COIL?

Does the media prefer APTA or COIL?

Which has more volatility and risk, APTA or COIL?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Which has more volatility and risk, APTA or HEMO?

Does the media prefer APTA or HEMO?

Is APTA or HEMO more profitable?

Which has stronger valuation and earnings, APTA or HEMO?

Do institutionals and insiders hold more shares of APTA or HEMO?

Summary

How does Aptamer Group compare to C4X Discovery?

Does the media favor C4XD or APTA?

Do institutionals and insiders hold more shares of C4XD or APTA?

Which has more risk & volatility, C4XD or APTA?

Is C4XD or APTA more profitable?

Which has better earnings and valuation, C4XD or APTA?

Summary

How does Aptamer Group compare to 4D pharma?

Which has better earnings and valuation, APTA or DDDD?

Do institutionals & insiders believe in APTA or DDDD?

Is APTA or DDDD more profitable?

Which has more volatility and risk, APTA or DDDD?

Does the media prefer APTA or DDDD?

Summary

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools